Disease Burden and Cost Consequence of Falls Among Individuals With Parkinson's Disease in Hong Kong: A Prospective Cost-utility Analysis
Disease Burden of Parkinson's Disease in Hong Kong
1 other identifier
observational
90
1 country
2
Brief Summary
Objective: Estimate the cost of disease and falls among people with Parkinson's disease living in Hong Kong. Design: Prospective cost-utility analysis (base year 2021) with one baseline and two follow-up assessments at 6 months and 12 months Participants: Community-dwelling participants with Parkinson's disease of both genders of any age. Intervention: Nil Outcome measures: Self-reported questionnaires will be used to obtain information about the healthcare utility. In addition, the number of falls, the severity of Parkinson' disease assessed using the MDS-Unified Parkinson's Disease Rating Scale, level of disability using the Hoehn and Yahr scale, balance using the Mini Balance Evaluation Systems Test and Activities-specific Balance Confidence (ABC) scale, risk of falls using Falls Efficacy Scale International and quality of life using the Short-form Health survey (SF-36) will be assessed. Predictors of cost include fall frequency, balance status, disease severity, level of disability, quality of life, and duration of disease. Analysis: A multiple regression analysis will be conducted to determine which predictor (independent variable) influence the overall cost. The level of statistical significance (α) will be set at p\<0.05. A Tornado plot will be constructed for the individual items of both direct and indirect cost having the minimum and maximum range set at the 25th and 75th percentile. Two-way analysis of variance (ANOVA) will assess the differences in healthcare cost among frequent, in-frequent and non-fallers. Spearman's or Pearson correlation coefficient will assess correlations between quality of life and healthcare cost; disease severity and healthcare cost; falls frequency and healthcare cost. Benefits to healthcare and health Cost-estimation highlights information required to enhance the health care service for the target population. Through a similar study among patients with cerebellar ataxia, our team demonstrated specific challenges that need additional support from the policy-makers such as employment following disability, visits to specialists, home-care, and community participation for people with cerebellar ataxia in Hong Kong. This study will highlight the strength and weakness of the current healthcare system to people of Hong Kong with Parkinson's disease, this will inform the challenges for the healthcare requiring additional attention which in turn will have a beneficial impact on the future service.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Nov 2023
Typical duration for all trials
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 17, 2021
CompletedFirst Posted
Study publicly available on registry
October 26, 2021
CompletedStudy Start
First participant enrolled
November 1, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2026
CompletedMarch 15, 2024
November 1, 2023
2.2 years
October 17, 2021
March 13, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Healthcare cost
We will estimate both direct and indirect cost using the self-reported questionnaires available in both English and Chinese languages. The following criteria were used to choose the individual items under direct and indirect costs: relevance to Parkinson's disease, relevance to falls and consequences of falls, how quantifiable the items are, based on the commonly estimated items in similar economic, and to the extent to which the item reflects and impacts the quality of life of people with Parkinson's disease.
Ongoing assessment from day 1 until 12 months
Secondary Outcomes (7)
Number of falls
Day 1 (T1), 6 months (T2) and 12 months (T3)
MDS-UPDRS
Day 1 (T1), 6 months (T2) and 12 months (T3)
Hoehn and Yahr scale
Day 1 (T1), 6 months (T2) and 12 months (T3)
MiniBESTest
Day 1 (T1), 6 months (T2) and 12 months (T3)
Falls Efficacy Scale International (FES-I)
Day 1 (T1), 6 months (T2) and 12 months (T3)
- +2 more secondary outcomes
Study Arms (1)
Observation group
Patients with a confirmed diagnosis of Parkinson's disease will be followed up for 12 months from the date of enrollment.
Interventions
Eligibility Criteria
Community-dwelling participants with a confirmed diagnosis of Parkinson's disease of both genders of any age and who are residing in Hong Kong
You may qualify if:
- community-dwelling participants with a confirmed diagnosis of Parkinson's disease
- both genders
- any age
- who are residing in Hong Kong.
You may not qualify if:
- are wheelchair-bound or bed-ridden,
- have atypical Parkinson's syndrome and
- other associated major illness such as stroke.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- The Hong Kong Polytechnic Universitylead
- Chinese University of Hong Kongcollaborator
- The University of Hong Kongcollaborator
- Parkinson's Disease Foundationcollaborator
Study Sites (2)
The Hong Kong Polytechnic University
Hung Hom, Kowloon, 00, Hong Kong
Prince of Wales Hospital
Shatin, Hong Kong
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Stanley J Winser, PhD
The Hong Kong Polytechnic Universit
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 17, 2021
First Posted
October 26, 2021
Study Start
November 1, 2023
Primary Completion
January 1, 2026
Study Completion
June 1, 2026
Last Updated
March 15, 2024
Record last verified: 2023-11
Data Sharing
- IPD Sharing
- Will not share
The personnel identification of the included participants will not be revealed. The study-related data will be expressed using a unique identification ID number. Personnel identifications such as names or photos will not be identified in public events such as conference presentations.